Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, is a severe form of fatty liver disease that affects roughly 5% of the global population. It occurs when fat builds up in the liver, triggering inflammation and scarring that can progress to cirrhosis, liver failure, and cancer. Despite its prevalence, there are very few treatment options available. The experimental drug DT-109, developed by researchers at the University of Michigan and collaborators, offers a new approach: instead of targeting the liver directly, it fixes the gut.
The logic is rooted in the gut-liver axis. In fatty liver disease, the intestinal lining becomes leaky — a condition known as increased intestinal permeability. This allows bacterial toxins, particularly endotoxins like lipopolysaccharides (LPS), to escape the gut and travel through the portal vein to the liver. Once there, they trigger an inflammatory cascade that worsens fat accumulation, fibrosis, and liver cell death. DT-109 is a tripeptide — a short chain of three amino acids — designed to strengthen the gut barrier and reduce this toxin leakage.
In the study, published in July 2026, researchers tested DT-109 in multiple animal models of MASH, including mice and rats fed high-fat, high-sugar diets. The results were striking. Animals treated with DT-109 showed significantly reduced liver fat, inflammation, and fibrosis compared to untreated controls. The drug also restored the integrity of the intestinal lining, reduced levels of circulating endotoxins, and shifted the gut microbiome toward a healthier composition.
What makes DT-109 particularly promising is its mechanism. Most experimental MASH drugs in development target metabolic pathways directly in the liver — reducing fat synthesis, increasing fat burning, or blocking inflammatory signals. While some have shown efficacy, they often come with side effects and limited response rates. By targeting the gut instead, DT-109 addresses what may be a root cause of the disease in many patients: a broken intestinal barrier that lets bacterial toxins into the bloodstream.
The gut-liver connection is increasingly recognized as central to metabolic health. A leaky gut has been linked not only to fatty liver disease but also to type 2 diabetes, obesity, and inflammatory bowel disease. If DT-109 proves safe and effective in human trials, it could represent a new class of therapies — gut-repairing drugs that treat liver disease from the inside out.
Knowledge takeaway: DT-109 is an experimental tripeptide drug that reversed severe fatty liver disease in animal studies by repairing the gut lining and preventing bacterial toxins from reaching the liver; it targets the gut-liver axis rather than the liver directly; the approach addresses a root cause of metabolic liver disease — intestinal barrier dysfunction; human trials are needed to confirm safety and efficacy.